Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity - PubMed (original) (raw)
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
G R Wilson et al. Br J Cancer. 2006.
Abstract
Overexpression and/or activity of c-Src non-receptor tyrosine kinase is associated with progression of several human epithelial cancers including breast cancer. c-Src activity in 'pure' ductal carcinoma in situ (DCIS) was measured to assess whether this predicts recurrence and/or correlates with HER2 expression and other clinical parameters. Activated c-Src levels were evaluated in DCIS biopsies from 129 women, with median follow-up at 60 months. High levels of activated c-Src correlated with HER2 positivity, high tumour grade, comedo necrosis and elevated epithelial proliferation. In univariate analysis, high activated c-Src level associated with lower recurrence-free survival at 5 years (P=0.011). Thus, high c-Src activity may identify a subset of DCIS with high risk of recurrence or progression to invasive cancer where therapeutics targeting c-Src may benefit this patient subset.
Figures
Figure 1
(Ai–v) Experimental controls for Clone 28 immunohistochemistry of activated c-Src. Pellets of untreated or doxycycline treated HCT116 colon cancer cells that express a doxycycline-inducible, wild-type (wt) c-Src. High levels of activated c-Src were detected in doxycyline treated HCT116 colon cancer cells harbouring the doxycycline-inducible wt c-Src (Aiii). Detectable but lower levels of active c-Src were detected in these HCT116 cells in the absence of doxycyline treatment (Aii). Induction of wt c-Src was independently confirmed by western blotting using an anti Src[pY418] antibody specific for autophosphorylated active c-Src (Figure 1A insert. No significant immunoreactivity was detected in HCT116 cells analysed by mouse IgG2a, which served as a negative control (Ai). Figure 1A(iv) shows a section of a MDA MB231 tumour xenograft negative control (IgG2A) and 1A(v) shows clone positive staining with Clone 28 in this xenograft indicative of high levels of activated c-Src. (Bi–iv) Immunohistochemistry for activated c-Src using clone 28 in normal breast epithelium (Bi), and DCIS tumours (Bii–iv). Low levels of activated c-Src in B(ii), moderate levels in B(iii) and high levels in B(iv). A higher level of activated c-Src was detected in DCIS tumours compared with normal breast. There was a positive correlation between the level of activated c-Src and tumour nuclear grade (P<0.0005). The scale bar equals 50 _μ_m.
Figure 2
In univariate analysis, Kaplain–Meier plot of cumulative local recurrence (DCIS and invasive breast carcinoma) for 129 patients with DCIS. Low-activated c-Src expressing DCIS tumours had a significant disease-free survival advantage over DCIS expressing moderate to high levels of activated c-Src.
Similar articles
- Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G. Curigliano G, et al. Ann Oncol. 2015 Apr;26(4):682-687. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18. Ann Oncol. 2015. PMID: 25600567 Clinical Trial. - Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Barnes NL, et al. Clin Cancer Res. 2005 Mar 15;11(6):2163-8. doi: 10.1158/1078-0432.CCR-04-1633. Clin Cancer Res. 2005. PMID: 15788662 - Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
Van Bockstal MR, Wesseling J, Lips EH, Smidt M, Galant C, van Deurzen CHM. Van Bockstal MR, et al. Breast Cancer Res. 2024 Aug 27;26(1):125. doi: 10.1186/s13058-024-01875-w. Breast Cancer Res. 2024. PMID: 39192322 Free PMC article. Review. - Is there a low-grade precursor pathway in breast cancer?
King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M. King TA, et al. Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21. Ann Surg Oncol. 2012. PMID: 21935747 - Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.
Wang SY, Shamliyan T, Virnig BA, Kane R. Wang SY, et al. Breast Cancer Res Treat. 2011 May;127(1):1-14. doi: 10.1007/s10549-011-1387-4. Epub 2011 Feb 15. Breast Cancer Res Treat. 2011. PMID: 21327465 Review.
Cited by
- Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.
Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Akkoc Mustafayev FN, et al. Eur J Breast Health. 2023 Oct 1;19(4):267-273. doi: 10.4274/ejbh.galenos.2023.2023-7-3. eCollection 2023 Oct. Eur J Breast Health. 2023. PMID: 37795002 Free PMC article. - Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
Nandi I, Smith HW, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V, Zuo D, Nam S, Attalla SS, Kim SH, Lusson S, Kuasne H, Fortier AM, Savage P, Martinez Ramirez C, Park M, Katzenellenbogen JA, Katzenellenbogen BS, Muller WJ. Nandi I, et al. J Clin Invest. 2023 Apr 3;133(7):e162324. doi: 10.1172/JCI162324. J Clin Invest. 2023. PMID: 36795481 Free PMC article. - SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.
Luo J, Zou H, Guo Y, Tong T, Ye L, Zhu C, Deng L, Wang B, Pan Y, Li P. Luo J, et al. Breast Cancer Res. 2022 Dec 29;24(1):99. doi: 10.1186/s13058-022-01596-y. Breast Cancer Res. 2022. PMID: 36581908 Free PMC article. Review. - Downregulation of Src-family tyrosine kinases by Srcasm and c-Cbl: A comparative analysis.
Lee V, Griffin TD, Suzuki-Horiuchi Y, Wushanley L, Kweon Y, Marshall C, Li W, Ayli E, Haimovic A, Hines A, Seykora JT. Lee V, et al. J Carcinog. 2021 Oct 11;20:21. doi: 10.4103/jcar.jcar_13_21. eCollection 2021. J Carcinog. 2021. PMID: 34729053 Free PMC article. - State-selective frustration as a key driver of allosteric pluripotency.
Byun JA, VanSchouwen B, Parikh N, Akimoto M, McNicholl ET, Melacini G. Byun JA, et al. Chem Sci. 2021 Jul 13;12(34):11565-11575. doi: 10.1039/d1sc01753e. eCollection 2021 Sep 1. Chem Sci. 2021. PMID: 34667558 Free PMC article.
References
- Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ (2005) Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 11: 2163–2168 - PubMed
- Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ (2001) Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20: 1465–1475 - PubMed
- Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12: 20–28 - PubMed
- Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 86: 429–438 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous